Evidence map›Paper›PMID 40597847›Full record

ArticleBMC cancer2025

Comprehensive multi-omics pan-cancer analysis revealed EGFLAM as a potential prognostic and immune infiltration-associated biomarker.

Jian Yang, Wenqian Xu, Shengyu Wang, Zhu Yu, Yue Feng, Da Li, Junqiang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jian Yang *Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Wenqian Xu *Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Shengyu WangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Zhu YuGuangxi Key Laboratory of Enhanced Recovery After Surgery for Gastrointestinal Cancer, Nanning, Guangxi Zhuang Autonomous Region, China.
Yue FengDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Da LiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Junqiang ChenDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China. chenjunqiang@gxmu.edu.cn.

Funding

Innovation Project of Guangxi Graduate Education No.YCBZ2025110The Guangxi Clinical Research Center for Enhanced Recovery after Surgery, Guangxi Science and Technology Base and Talent Project No.AD19245196The Guangxi key Laboratory of Enhanced Recovery after Surgery for Gastrointestinal Cancer No.YYZS2020003The Guangxi Key Research and Development Project No.AB24010149The National Natural Science Foundation of China No.82060430The National Natural Science Foundation of Guangxi No.2023GXNSFBA026164
6 · The paper itself

Abstract

EGFLAM is a versatile protein widely expressed in multiple human tissues, yet its function in pan-cancer is not fully understood. To investigate the molecular function of EGFLAM, a comprehensive pan-cancer analysis was carried out using several public databases and bioinformatics tools. Ultimately, confirmatory experiments were conducted in vitro with gastric cancer cell lines. The results showed that EGFLAM expression was elevated in multiple cancer types, especially gastric cancer. It also demonstrated prognostic predictive value in several cancer types, suggesting its potential as a prognostic biomarker. The dysregulation of EGFLAM expression observed in certain cancers might be attributed to factors such as promoter methylation changes, mRNA methylation modifications, and genetic alterations of the EGFLAM locus. EGFLAM expression was associated with Immune cell infiltration, immune checkpoints, tumor mutation burden (TMB), and microsatellite instability (MSI). Single-cell analysis of gastric cancer showed that EGFLAM was predominantly expressed in fibroblast populations. Functional enrichment analyses (GO/KEGG) demonstrated EGFLAM involvement in extracellular matrix receptor interactions and PI3K-AKT signaling pathway. RT‒qPCR confirmed EGFLAM upregulation in gastric cancer specimens compared to normal controls. In vitro functional assays revealed that EGFLAM knockdown significantly suppressed gastric cancer cell proliferation, migration, and invasion while inducing apoptosis. Collectively, our multi-omics analyses delineated EGFLAM's oncogenic functions across cancer types, positioning it as both a promising prognostic biomarker and a potential therapeutic target for gastric cancer.

Indexed as

Biomarkers, TumorNeoplasmsStomach NeoplasmsApoptosisCell Line, TumorCell MovementCell ProliferationDNA MethylationGene Expression Regulation, NeoplasticHumansMultiomicsPrognosisSignal TransductionBiomarkers, TumorBiomarkerEGFLAMGastric cancerImmune infiltrationPan-cancerPrognosis

Identifiers

PMID40597847
PMCPMC12211248

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.